|Bid||44.10 x 500|
|Ask||44.11 x 1600|
|Day's Range||43.89 - 44.14|
|52 Week Range||37.20 - 45.58|
|PE Ratio (TTM)||50.43|
|Dividend & Yield||1.95 (4.50%)|
|1y Target Est||N/A|
These are the stocks posting the largest moves before the bell.
A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed. A federal jury in Wilmington, Delaware on Tuesday found that Teva willfully infringed the patent in connection with its sales of a generic version of the drug with a label indicating it could be used for treating chronic heart failure. The jury rejected Teva's contention that the patent was invalid.
Given the company’s industry leading position, solid fundamentals and attractive stock valuation, we view it as a preferable alternative to traditional competitors in its industry.